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Birt-Hogg-Dube´ syndrome (BHD), a genodermatosis characterized by multiple hamartomas of the hair follicle
(fibrofolliculoma), predisposes individuals to an increased risk of developing renal neoplasms and spontaneous
pneumothorax. Previously, we localized the BHD locus (also known as FLCN) to chromosome 17p11.2 by linkage
analysis and subsequently identified germline mutations in a novel gene in probands from eight of the nine families
with BHD in our screening panel. Affected members of five of the families inherited an insertion/deletion of a
cytosine in a C8 tract in exon 11. This mutation was also identified by exon 11 screening in probands from 22 of
52 additional families with BHD and therefore represents a hypermutable “hotspot” for mutation in BHD. Here,
we screened the remaining 30 families from this large BHD cohort by direct sequence analysis and identified
germline BHD mutations in 84% (51/61) of all families with BHD recruited to our study. Mutations were located
along the entire length of the coding region, including 16 insertion/deletion, 3 nonsense, and 3 splice-site mutations.
The majority of BHD mutations were predicted to truncate the BHD protein, folliculin. Among patients with a
mutation in the exon 11 hotspot, significantly fewer renal tumors were observed in patients with the C-deletion
than those with the C-insertion mutation. Coding-sequence mutations were not found, however, in probands from
two large families with BHD whose affected members shared their family’s BHD-affected haplotype. Of the 53
families with BHD whose members inherited either a germline mutation or the affected haplotype, 24 (45%) had
at least one member with renal neoplasms. Three families classified with familial renal oncocytoma were identified
with BHD mutations, which represents the first disease gene associated with this rare form of renal neoplasm. This
study expands the BHD-mutation spectrum and evaluates genotype-phenotype correlations among families with
BHD.
Introduction
Birt-Hogg-Dube´ syndrome (BHD [MIM 135150]) was
first described in 1977 by three Canadian physicians who
studied a large family whose members were affected with
multiple, small papules on the face, neck, and upper
torso that developed after age 25 years (Birt et al. 1977).
These lesions, called “fibrofolliculomas” (FFs), were char-
acterized as benign hamartomas of the hair follicle. His-
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tologically, FFs are characterized by strands of prolif-
erating epithelial cells extending out from the infundibu-
lum of the hair follicle, surrounded by a thick mantle
of connective tissue and mucin-rich stroma (Birt et al.
1977). FFs are part of the triad of BHD skin lesions that
also includes trichodiscomas and acrochordons. BHD is
inherited in an autosomal dominant manner and has
been reported to be associated with renal tumors (Roth
et al. 1993; Toro et al. 1999), spontaneous pneumotho-
rax (Binet et al. 1986; Toro et al. 1999), colon polyps,
and colon carcinomas (Hornstein and Knickenberg 1975;
Hornstein 1976; Rongioletti et al. 1989; Le Guyadec et
al. 1998). A recent risk-assessment study of BHD-af-
fected patients concluded that a diagnosis of BHD con-
ferred a 7-fold increased risk of developing renal neo-
plasia and a 50-fold increased risk of spontaneous pneu-
mothorax but no increased risk of colon polyps or colon
cancer (Zbar et al. 2002). Renal tumors with a variety
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of histologies are associated with BHD, includingchromo-
phobe renal cell carcinoma (RCC), benign renal onco-
cytoma, clear-cell RCC, and papillary type I RCC (Pav-
lovich et al. 2002, 2005). The most common form of
renal tumor seen in patients with BHD is an oncocytic
hybrid tumor with areas reminiscent of both chromo-
phobe RCC and oncocytoma (Tickoo et al. 1999).
The BHD disease locus was mapped to chromosome
17p11.2 by genetic linkage analysis (Khoo et al. 2001;
Schmidt et al. 2001); we subsequently identified germ-
line mutations in a novel gene (BHD [GenBank acces-
sion number AF517523], or FLCN [MIM 607273]) in
a panel of nine kindreds with BHD. These were inser-
tions, deletions, and nonsense mutations that were pre-
dicted to truncate the BHD protein, folliculin (Nicker-
son et al. 2002). A majority of kindreds with BHD were
found to harbor an insertion or deletion of a cytosine
in a C8 tract within exon 11, suggesting a hypermutable
“hotspot” for mutation in BHD (Khoo et al. 2002;
Nickerson et al. 2002).
Folliculin, is a 579-aa protein with no known func-
tional domains, for which mouse, fly, worm, yeast, dog,
and rat orthologs have been identified (Nickerson et al.
2002; Lingaas et al. 2003; Okimoto et al. 2004). BHD
mRNA expression, measured by fluorescent in situ hy-
bridization, is widespread in a variety of tissues, in-
cluding skin and its appendages, the distal nephron of
the kidney, and stromal cells and type I pneumocytes
of the lung (Warren et al. 2004). Strong BHD mRNA
expression was found in secretory cells, such as acinar
cells of the parotid gland and pancreas, and ductal cells
of the breast. Reduced BHD expression was seen in
renal tumors from patients with BHD, regardless of his-
tologic type.
Sixty-one families affected with BHD were recruited
to the NCI for study over a 3-year period. Previously,
we evaluated a screening panel representing nine of
these families with BHD and reported the identification
of one nonsense and two frameshift BHD mutations as
well as five insertion/deletion mutations in the C8 tract
of exon 11. Exon 11 screening of the entire cohort of
families revealed C8 tract insertion/deletion mutations
in probands from 22 of the 52 remaining families with
BHD (Nickerson et al. 2002). In the present study, we
have completed the mutation analysis of this large BHD
cohort by screening, by direct sequence analysis, the
remaining 30 families for mutations in the BHD gene.
We have identified germline BHD mutations in affected
members of 84% (51/61) of kindreds with BHD evalu-
ated to date. In addition, we have collected phenotypic
information on family members and have correlated
phenotype with germline BHD mutation to evaluate
possible genotype-phenotype associations.
Methods
Patient Recruitment
We recruited members of 61 BHD-affected families to
our study at the NCI, from 1998 to 2001, through pa-
tient recruitment letters to dermatologists (55 families)
and by referrals from urologic surgeons (6 families). All
of the families with BHD were invited to participate in
the study regardless of the number of affected individuals
in the family or the presence or absence of associated
health problems. A family was considered affected with
BHD if it had (1) one or more members with 10 or more
skin lesions that were clinically compatible with FFs and/
or (2) a minimum of one histologically proven FF. His-
tologically, an FF was characterized by multiple anas-
tomosing strands of 2–4 epithelial cells extending from
a central hair follicle. Phenotypic expression of BHD
skin papules can be variable among affected members
of a family with BHD; therefore, once a proband with
clinically positive or histologically proven FFs was iden-
tified in a BHD-affected family, other family members
were screened and classified as affected for genotype-
phenotype evaluation on the basis of (1) the presence of
a histologically proven FF, (2) inheritance of the family’s
germline BHD mutation, (3) inheritance of the family’s
BHD-affected haplotype, or (4) obligate carrier status.
We also included family 238 as affected with BHD, be-
cause multiple members were affected with bilateral, re-
nal oncocytic hybrid neoplasms, a rare histologic variant
uniquely associated with BHD. Participants in this study
provided written informed consent. The protocol was
approved by the institutional review boards of the NCI
and the University of Manitoba.
Patient Evaluation
All members of families with BHD who were aged
120 years were evaluated at the NIH Clinical Center
and/or in the field. Blood samples were obtained for
DNA extraction and mutation analysis. Each patient re-
ceived a detailed dermatologic examination, and biop-
sies were performed for lesions suspected to be FFs.
Family members seen at the NIH were evaluated for
other phenotypic manifestations associated with BHD.
Occult renal malignancies were detected by CT scan of
the abdomen before and after administration of ∼120
ml of Ioxilan 300 (Cook Imaging). The presence of lung
cysts and evidence of spontaneous pneumothorax were
evaluated by thoracic CT scan, by use of high-resolution
sections (1 mm) through the chest at 10-mm intervals.
Additional information was obtained from patient medi-
cal histories, outside medical records, and tissue speci-
mens obtained for NIH pathology review.
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Mutation Analysis of the BHD Gene
DNA was extracted from peripheral-blood leukocytes,
in accordance with standard procedures. Exon/intron
structure of the BHD gene was determined by BLAST
alignment of two overlapping, uncharacterized, full-
length transcripts from skin melanoma (GenBank acces-
sion numbers BC015725 and BC015687), against the
BAC clone RP11-45M22 (GenBank accession number
AC055811); intronic primers were designed to amplify
14 coding exons and splice junctions for sequencing, as
described elsewhere (Nickerson et al. 2002). Subsequent
analyses showed that this exon/intron structure matched
the cloned full-length BHD transcript. PCR products
were generated using standard conditions and were pu-
rified; double-stranded sequencing was performed using
BigDye Terminators (Applied Biosystems), as described
elsewhere (Nickerson et al. 2002). Sequence variants
were examined for cosegregation with disease in their
respective families by denaturing high-performance liq-
uid chromatography or by single-stranded sequencing.
Insertions and deletions were subcloned with Topo Clon-
ing Kit (Invitrogen) and were sequenced. At least 160
unaffected individuals were examined for each disease-
associated sequence variant.
BHD Haplotype Carrier Analysis
Family members were evaluated for inheritance of the
BHD-affected haplotype in cases in which a BHD germ-
line mutation was not identified in the proband. To de-
termine if a family member inherited the BHD-affected
haplotype, individuals were genotyped using seven mi-
crosatellite markers (D17S953, D17S740, [location of
BHD] D17S2196, D17S620, AGAT100, D17S805, and
D17S1824) that spanned an 8-cM distance flanking the
BHD locus on chromosome 17p. Haplotypes were de-
termined from the genotype order in which the least
number of recombinants occurred. All members of BHD-
affected families who presented with FFs inherited the
family’s BHD-affected haplotype.
Statistical Analysis
The percentage of BHD-affected individuals with re-
nal tumors was calculated in two ways: (1) by dividing
the number of BHD-affected individuals with renal tu-
mors by the number of BHD-affected individuals seen
at the NIH and in the field, and (2) by dividing the
number of BHD-affected individuals who had renal tu-
mors by the number of BHD-affected individuals who
were screened by abdominal CT scan. To overcome se-
lection bias, we assessed the frequency of renal tumors
found in patients with BHD two ways. Generally, pa-
tients who were affected with BHD skin lesions and/or
were symptomatic for renal tumor came to the NIH to
be seen and screened. Some patients who were less se-
verely affected did not come to the NIH and were seen
only in the field and therefore did not undergo abdominal/
pulmonary CT screening. Differences in frequency of
renal tumors, pneumothorax, or lung cysts between the
groups with exon 11 C-insertion and C-deletion muta-
tions were tested with Fisher’s exact test (two-sided) (see
the Calculation of Fisher’s Exact Test Web site). P !
was considered statistically significant..05
Results
Description of Patients
For the present study, 219 individuals (110 females
and 109 males) from 53 families (whose members in-
herited either a germline mutation or the affected hap-
lotype) were classified as affected with BHD. Of those
individuals, 187 were evaluated in the field or at the
NIH Clinical Center. Data were available for 7 deceased
individuals with obligate carrier status, 12 individuals
were evaluated by outside dermatologists, and 10 in-
dividuals provided a blood sample for mutation analysis
but did not undergo further medical evaluation at the
NIH.
The number of affected individuals in a family ranged
from 1 to 25. In the present study, the largest number
(25) of affected family members in a family with BHD
was found in the Canadian family with BHD, family 172,
originally studied by Drs. Birt, Hogg, and Dube´ (Birt et
al. 1977). Twenty-four families had only one member
affected with BHD.
Dermatologic Manifestations
The hallmark BHD cutaneous manifestation is a be-
nign tumor (hamartoma) of the hair follicle, an FF. Of
the 175 BHD-affected individuals whose skin papules
were biopsied and evaluated histologically, 147 (84%)
were diagnosed with a histologically proven FF. All fami-
lies that carried a BHD mutation or inherited the af-
fected haplotype contained individuals who developed
BHD skin lesions, with the exception of one family, fami-
ly 238, referred to the NCI by the proband’s urologist,
in which three sisters developed bilateral renal oncocytic
hybrid neoplasms and lung cysts without evidence of
FFs. In the present study, the cutaneous lesions were not
found in patients aged !20 years.
Pulmonary Manifestations
A high percentage of patients with BHD develop air-
filled lung cysts (Zbar et al. 2002) and have a 50-fold
higher risk of developing spontaneous pneumothorax.
In the present study, 64 (32%) of 198 BHD-affected
individuals for whom medical history was available had
a history of spontaneous pneumothorax. Of the 129
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BHD-affected individuals who were screened by pulmo-
nary CT scan, 110 (85%) were found to have one or
more lung cysts consistent with the BHD phenotype.
Forty-five (85%) of 53 families with BHD germline mu-
tations or affected-haplotype carriers had members who
developed lung cysts or spontaneous pneumothorax.
Renal Neoplasia in BHD
BHD is unique among inherited renal cancer syndromes
because patients develop not one, but a variety of his-
tologic types of renal tumors, including chromophobe
RCC, renal oncocytoma, clear-cell RCC, and papillary
RCC (Pavlovich et al. 2002, 2005). Most often, BHD-
associated renal neoplasms are oncocytic hybrid tumors,
comprising elements of both chromophobe and renal
oncocytoma. Thirty-eight BHD-affected individuals rep-
resenting 24 BHD-affected families developed renal tu-
mors. Males developed renal tumors 2.5-fold more often
than did females (27 males; 11 females). The median
age at diagnosis was 48 years (range 31–71 years). Tu-
mors developed both bilaterally with multiple foci and
unilaterally with a single focus. The number of patients
with renal neoplasia in a BHD-affected family ranged
from one to three, most frequently one case per family.
The frequency of renal tumor among BHD-affected in-
dividuals seen at the NIH or in the field was 20% (38/
187). The frequency of renal tumor among BHD-af-
fected individuals who were evaluated by CT scan was
29% (38/132). Overall, 45% (24/53) of BHD-affected
families with germline BHD mutations or affected-hap-
lotype carriers contained individuals who were affected
with renal tumors.
Other Phenotypic Features Found in BHD-Affected
Individuals
There are reports that describe a number of additional
phenotypic manifestations in BHD-affected individuals,
including colon polyps and colon carcinoma (Hornstein
and Knickenberg 1975; Hornstein 1976; Rongioletti et
al. 1989; Le Guyadec et al. 1998), lipomas (Chung et
al. 1996; Toro et al. 1999), angiolipomas (Chung et al.
1996), parathyroid adenomas (Chung et al. 1996), and
parotid oncocytomas (Liu et al. 2000). Among the 219
BHD-affected individuals in the present study, four pa-
rotid gland tumors were reported in 2 men (diagnosed
at ages 20 and 39 years) and 2 women (diagnosed at
ages 62 and 72 years). Three of the parotid tumors were
classified as oncocytomas. Additionally, three individu-
als with lipomas and nine individuals with colon polyps/
carcinoma were identified through medical history.
Variable Expression of Phenotypic Manifestations
BHD is characterized by FFs, lung cysts, spontaneous
pneumothorax, and an increased risk of developing renal
neoplasia. These manifestations may occur singly or in
various combinations in a patient, and variable phe-
notypic expression may be observed among family mem-
bers from the same BHD-affected family. Among the 53
families with BHD whose affected members had a BHD
germline mutation or carried the BHD-affected haplo-
type, 22 (41.5%) of the families had skin, lung, and renal
manifestations, 22 (41.5%) of the families had members
with skin and lung phenotypic features, 1 (2%) of the
families had renal and lung phenotypic features, 7 (13%)
of the families had only skin papules, and 1 (2%) of the
families had renal tumors and skin papules (table 1).
BHD-Mutation Spectrum and Mutational Hotspot
Elsewhere, we reported the identification of BHD germ-
line mutations, by direct sequence analysis, in 30 of 61
families with BHD recruited to the NCI (Nickerson et
al. 2002). In the present study, we have completed mu-
tation analysis of the remaining 30 families and, to date,
have identified germline BHD mutations in 51 (84%) of
61 families with BHD in the NCI cohort. Each family’s
mutation cosegregated with disease and was not found
in at least 160 unaffected individuals. Altogether, 22
novel mutations have been identified (5 were reported
elsewhere [Nickerson et al. 2002]), including 16 inser-
tions or deletions that cause frameshifts leading to pre-
mature truncation of the protein, 3 nonsense mutations
that encode early termination codons, and 3 putative
splice-site mutations (table 1 and fig. 1). Of note, no
germline missense BHD mutations were detected in these
BHD-affected families.
A total of 53% (27/51) of families with a germline
BHD mutation had a cytosine insertion (c.1733insC [18
families]) or deletion (c.1733delC [9 families]) in the
mononucleotide tract of eight cytosines (c.1733–1740)
in exon 11. This mutational hotspot has been identified
by several laboratories (Khoo et al. 2002; Nickerson et
al. 2002). Mononucleotide tracts are thought to be hy-
permutable due to slippage of the DNA polymerase dur-
ing replication (Streisinger et al. 1966), which results in
frameshift mutations leading to protein truncation. Al-
though most of the mutations identified in the remaining
24 BHD-affected families were unique, 2 families had
the same 28-bp duplication in exon 9 (c.1378–1405
dup), 3 families shared a nonsense mutation in exon 12
(c.1844CrG), and 2 families shared a putative splice-
site mutation in intron 9 (IVS92TrG) (table 1 and fig.
1).
Genotype-Phenotype Correlation: Location
within the BHD Gene
Mutations were identified in all translated exons (ex-
ons 4–14), with the exception of exons 8 and 10 (fig.
2). Exon 11 was the most frequent site of mutation in
Table 1
BHD Germline Mutations and Phenotypes of Families with BHD
FAMILY
MUTATION ANALYSIS NO. OF FAMILY MEMBERS WITH PHENOTYPE
Exon Nucleotidea Change
Codonb
Location
Typec
(aarter)
Total
Affected FFd
Renal
Tumors
Lung
Cystse PTf
220 4 c.513delT F20 FS (34) 1 1g 0 ND 0
249 5 IVS4-1GrA G84 SS 3 1 1 ND 2
8188 5 c.707delC G84 FS (45) 2 2 0 2 0
209 5 c.751delA D99 FS (30) 2 2 0 1 0
233 6 c.1036delG G195 FS (27) 1 1 0 1 0
202 7 c.1087delAGinsC E211 FS (11) 8 7 1 5 0
224 7 c.1092delT F213 FS (9) 1 1 0 1 0
166 7 c.1126delCA T224 FS (22) 4 4 3 4 0
217 9 c.1378-1405dup T317 FS (79) 1 1 1 1 0
228 9 c.1378-1405dup T317 FS (79) 12 11 2 7 4
231 9 c.1468delG W338 FS (14) 2 2 0 2 1
225 9 c.1473delC R341 FS (11) 1 1g ND ND 0
242 9 IVS91GrA V355 SS 9 6 1 7 8
229 9 IVS92TrG V355 SS 5 5 3 4 1
238 9 IVS92TrG V355 SS 3 0 3 3 0
239 11 c.1733insC H429 FS (26) 1 1 1 1 1
8244 11 c.1733insC H429 FS (26) 1 1g 0 1 0
8319 11 c.1733insC H429 FS (26) 1 1 0 1 0
7561 11 c.1733insC H429 FS (26) 1 1h ND ND 0
187 11 c.1733insC H429 FS (26) 1 1 1 1 0
7399 11 c.1733insC H429 FS (26) 1 1 0 0 0
250 11 c.1733insC H429 FS (26) 3 2 1 1 1
246 11 c.1733insC H429 FS (26) 8 8g 0 0 2
191 11 c.1733insC H429 FS (26) 1 1h ND ND 0
211 11 c.1733insC H429 FS (26) 1 1 0 1 0
241 11 c.1733insC H429 FS (26) 4 4 1 4 0
183 11 c.1733insC H429 FS (26) 1 1 1 ND 1
208 11 c.1733insC H429 FS (26) 1 1 0 1 0
167 11 c.1733insC H429 FS (26) 3 1 2 3 2
210 11 c.1733insC H429 FS (26) 11 6 0 2 6
174 11 c.1733insC H429 FS (26) 10 8 3 9 0
216 11 c.1733insC H429 FS (26) 16 11 2 8 8
200 11 c.1733insC H429 FS (26) 7 3 1 2 4
232 11 c.1733delC H429 FS (38) 5 4 0 4 0
248 11 c.1733delC H429 FS (38) 3 2 ND ND 1
234 11 c.1733delC H429 FS (38) 2 2 0 2 2
176 11 c.1733delC H429 FS (38) 1 1 0 1 1
226 11 c.1733delC H429 FS (38) 1 1 0 0 0
175 11 c.1733delC H429 FS (38) 1 1 0 1 0
184 11 c.1733delC H429 FS (38) 1 1 1 1 0
201 11 c.1733delC H429 FS (38) 6 5 0 4 0
185 11 c.1733delC H429 FS (38) 7 3 ND 1 5
6932 12 c.1758delT F435 FS (32) 1 1 1 1 1
7416 12 c.1834delTC L460 FS (24) 1 1 0 1 0
230 12 c.1844CrG Y463X NS 9 7 1 2 2
188 12 c.1844CrG Y463X NS 2 2 0 2 1
245 12 c.1844CrG Y463X NS 2 2 0 ND 1
8015 12 c.1881insG D476 FS (9) 1 1 1 ND 0
7707 12 c.1884CrT R477X NS 1 1g ND ND 1
7706 13 c.1945insCTGT V497 FS (24) 1 1g ND ND 0
168 14 c.2034CrT R527X NS 5 1 3 3 1
172 NFi BHD haplotype NA NA 25 17 1 10 6
240 NFi BHD haplotype NA NA 17 8 2 4 1
NOTE.— determined or no CT scan available; applicable.NDp not NAp not
a Nucleotide numbering according to GenBank accession number AF517523. Nucleotide 456 corresponds to A
of ATG initiation codon. In cases of ins/del in a mononucleotide tract, the first nucleotide of the tract is given.
b First codon affected by sequence variation. The codon for initiator methionine is codon 1.
c (missense amino acids to predicted premature termination codon); site;FSp frameshift SSp splice NSp
.nonsense
d FF diagnosis based on histology, except where indicated.
e Diagnosis based on thoracic CT scan.
f pneumothorax episodes.PTp spontaneous
g FF diagnosis based on clinical evaluation only.
h Positive BHD diagnosis based on 180 trichodiscomas.
i found.NFp not
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Figure 1 BHD mutations in affected families. Sequencing chromatograms of genomic DNA of patients with BHD are shown on the left
(the arrow indicates position of nucleotide variation), and family pedigrees are shown on the right. Quadrants within pedigree symbols indicate
presence of FFs (blue), lung cysts/pneumothorax (yellow), and/or renal tumor (red) in each family member. -type BHD sequence;WTp wild
determined; diagonal . A, Mutation in a splice-donor site in intron 9 (IVS92TrG) is predicted to cause exonNDp not linep deceased
skipping. B and C, Mutations at c.2034CrT and c.1844CrG encode premature termination codons predicted to truncate the BHD protein.
D, A 2-bp deletion, c.1126delCA, will cause a shift in the reading frame and lead to a premature stop codon downstream, truncating the BHD
protein.
the 51 BHD-affected families (27 families had the hot-
spot mutation), exons 9 and 12 were each the site of
mutations in 7 families, and exons 5 and 7 were each
the site of mutations in 3 families. Exons 4, 6, 13, and
14 were each the site of one unique mutation in a BHD-
affected family. Eight (16%) of the families had muta-
tions in the 5′ half, and 43 (84%) of the families had
mutations in the 3′ half of the BHD gene.
The most 5′ mutation occurred at nt 513 (c.513delT)
in exon 4 (20 aa from the initiation codon) in family
7306 (fig. 2). This frameshift mutation was predicted to
truncate the protein 34 aa (missense) downstream. The
affected individual in this family developed only BHD
skin manifestations, without the other phenotypic fea-
tures. The most 3′ mutation occurred at nt 2034 (c.2034
CrT) in exon 14 (family 168) and was predicted to
produce a premature termination codon at codon 527,
eliminating only 52 aa from the full-length protein (fig.
1b). Nonetheless, full expression of the BHD phenotype
was observed in family 168; three affected members de-
veloped renal neoplasia and lung cysts, and one was
diagnosed with FF. Interestingly, the other nonsense
mutations predicted to produce premature termination
codons were located in exon 12 (c.1844CrG and
c.1884CrT), also near the 3′ end of the BHD gene.
Renal tumors were found in 5 (14%) of the mutation
carriers with mutations in the 5′ half of the BHD gene
and in 30 (86%) of the mutation carriers with mutations
in the 3′ half of the BHD gene. Renal tumors were pres-
ent in patients with frameshift mutations (insertion or
deletion), nonsense mutations, and splice-site mutations
in BHD. Of patients with spontaneous pneumothorax,
97% (55/57) inherited mutations in the 3′ half of the
BHD gene (table 1), and frameshift, nonsense, and
splice-junction mutations were represented among those
affected individuals.
Genotype-Phenotype Correlation: Mutational Hotspot
The most frequently mutated site in BHD was a cy-
tosine insertion or deletion in the C8 tract of exon 11
(c.1733insC or c.1733delC), identified in 27 BHD-af-
fected families. We estimated the frequency of develop-
ing FFs, lung cysts, spontaneous pneumothorax, or renal
tumors in BHD-affected family members with the C-
insertion mutation compared with those individuals with
the C-deletion mutation (fig. 3). A total of 64 individuals
carried the C-insertion mutation, and 27 individuals car-
ried the C-deletion mutation. The frequency of histo-
logically proven FFs among those individuals whose le-
sions were biopsied was similar among C-insertion–mu-
tation carriers (83% [44/53]) and C-deletion–mutation
carriers (87% [20/23]). The frequency of pneumothorax
episodes was also similar between carriers of C-insertion
(37% [23/62]) and C-deletion (35% [9/26]) mutations.
Lung cysts were detected on thoracic CT scans in 88%
(35/40) of C-insertion–mutation carriers, compared with
77% (13/17) of C-deletion–mutation carriers, which is
not significantly different. However, we noted that renal
tumors developed in significantly fewer C-deletion–mu-
tation carriers than C-insertion–mutation carriers.Among
C-deletion carriers, only 6% (1/16) of those who were
evaluated by CT scan (4% [1/26] of those seen at the
NIH or in the field) developed renal tumors. By com-
parison, 33% (13/40) of C-insertion–mutation carriers
who were evaluated by CT scan (23% [13/56] of those
seen at the NIH or in the field) developed renal tumors
( ) (fig. 3). The median age (46.5–50 years) ofPp .03
patients with BHD seen at the NIH was similar for men
and women with the C-insertion and the C-deletion mu-
tations, and the number of males and females in each
mutation group was approximately equal.
Genotype-Phenotype Correlation: Putative Splice-Site
Mutation in IVS9
Two apparently unrelated families were found to have
a putative splice-site mutation in the BHD gene within
intron 9, IVS92TrG (table 1 and fig. 1a). Renal-tumor
frequency in the affected members of families 229 and
238 was 3/5 and 3/3, respectively, which raises the pos-
sibility that this splice-site mutation might be associated
with a higher frequency of renal tumors. A third family
(family 242) inherited a different nucleotide change in
the same splice-donor site (IVS91GrA) and had a re-
nal-tumor frequency of 1/9 (table 1).
Linkage to 17p11.2 without Detectable BHD Mutation
in Two Large Families with BHD
We screened 61 families with BHD that were affected
with histologically proven FFs, and we found germline
BHD mutations in 51 families. Two additional families,
however, showed linkage to chromosome 17p11.2 by
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Figure 2 BHD exon-intron structure showing the location of germline mutations identified in 51 families with BHD. Frameshift (red)
and nonsense (blue) mutations, predicted to prematurely truncate the BHD protein, were identified along the entire length of the coding region
(exons 4–14). Splice-site (yellow) mutations predicted to cause exon skipping were identified in introns 4 and 9. The insertion or deletion of a
cytosine in a C8 tract in exon 11 was identified in 27 of 51 families with BHD mutations.
haplotype analysis with polymorphic microsatellite mark-
ers, but we were unable to detect a sequence variation
in the BHD gene by direct sequence analysis. Evidence
of heterozygosity at a number of informative SNP loci
reduced the possibility of intragenic deletion in these fami-
lies, although this deletion cannot be absolutely ruled out.
Family 172 is the original Canadian family described
by Drs. Birt, Hogg, and Dube´ (Birt et al. 1977) and was
used in linkage analysis studies that identified the BHD-
disease locus on 17p11.2 (LOD score 4.98 at marker
D17S740; ) (Schmidt et al. 2001). Twenty-five fami-vp 0
ly members had the same BHD-affected haplotype over
an 8.5-cM region of chromosome 17p11-12 (Schmidt et
al. 2001). However, direct sequencing of the 14 coding
exons revealed no BHD sequence variation in periph-
eral-blood DNA from affected members of family 172.
All family members whose lesions were biopsied had at
least one histologically proven FF; one affected family
member developed a renal tumor, and six members had
a history of pneumothorax (table 1).
In family 240, a large family with BHD recruited to
the NCI study, eight family members were identified with
histologically proven FFs (Lindor et al. 2001). Upon ge-
notyping with six polymorphic microsatellite markers
flanking the BHD locus, from D17S953 to D17S1824,
17 members were found to inherit the BHD-affected
haplotype on chromosome 17p11.2 (data not shown).
One BHD-haplotype carrier had a history of pneumo-
thorax, two developed renal tumors, and four were
found, on thoracic CT scan, to have lung cysts (table
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Figure 3 Frequency of BHD phenotypic manifestations in pa-
tients with the C-insertion mutation versus the C-deletion mutation in
the C8 tract of exon 11. Patients with the c.1733delC mutation de-
veloped renal tumors at a significantly lower frequency than did pa-
tients with the c.1733insC mutation ( ). Hatched bar indicatesPp .03
c.1733insC mutation carriers ( ); blackened bar indicatesnp 64
c.1733delC mutation carriers ( ); unblackened bar indicates allnp 27
BHD-mutation/haplotype carriers ( ), included for compari-np 219
son. Renal tumors were identified from medical histories, surgical re-
ports, and abdominal CT scans. Spontaneous pneumothorax episodes
were determined by patient history and thoracic CT scans. Lung cysts
were identified by thoracic CT scans. Skin biopsies were evaluated by
a dermatologist for FF-positive histology.
1). Complete sequencing of BHD in DNA from affected-
haplotype carriers in family 240 did not reveal any se-
quence variation.
Discussion
In the present study, we completed BHD-mutation an-
alysis, by direct sequencing, of 30 families with BHD
that were recruited to the NCI. To date, we have iden-
tified mutations in 84% (51/61) of all families with BHD
who were studied at the NCI, including 16 novel inser-
tion/deletion mutations, 3 nonsense mutations, and 3
putative splice-site mutations. The majority of these mu-
tations were predicted to prematurely terminate follicu-
lin and to result in loss of function, suggesting that BHD
may act as a tumor-suppressor gene.
These data support other lines of evidence that point
to a tumor-suppressor role for BHD. The majority of
germline BHD mutations reported to date are inacti-
vating frameshift and nonsense mutations (Khoo et al.
2002; Nickerson et al. 2002; the present study). Loss
of the wild-type BHD allele (loss of heterozygosity
[LOH] 17%) or somatic frameshift second-hit muta-
tions (53%) were confirmed in 77 BHD-associated renal
tumors from kindreds with BHD (Vocke et al., in press),
resulting in biallelic inactivation of BHD. A novel so-
matic mutation was identified in a BHD-related chromo-
phobe RCC from an affected member of a family with
BHD (Khoo et al. 2002). Additionally, two animal stud-
ies of BHD have been described that support a tumor-
suppressor function for the BHD protein, the Nihon rat
renal cancer model (Okimoto et al. 2000, 2004; Hino
et al. 2001) and canine hereditary renal cystadenocar-
cinoma and nodular dermatofibrosis in the German shep-
herd (Lium and Moe 1985; Jonasdottir et al. 2000;
Lingaas et al. 2003). Germline disease-cosegregating
mutations have been identified in the Bhd rat and dog
orthologs that lead to renal-tumor development in these
animal models of BHD. The germline frameshift mu-
tation in the Nihon rat Bhd ortholog is predicted to
prematurely truncate the encoded protein.
We noted that, among the 53 BHD-affected families,
no disease-associated missense mutations in the BHD
gene were found. One possible explanation is that mis-
sense BHD mutations that lead to amino acid substi-
tutions may have little or no effect on folliculin function,
thereby producing either a mild (undetectable) pheno-
type or no phenotype at all.
No correlation between BHD phenotype and location
of the mutation was found. We found disease-associated
mutations along the entire length of the BHD gene,
within 9 of the 11 coding exons. The location of the
mutation did not affect the phenotypic expression of
BHD. Renal tumors, lung cysts, spontaneous pneumo-
thorax, and FFs developed in patients with mutations
in both the 5′ half and the 3′ half of the gene. Since
these mutations were predicted to introduce a prema-
ture termination codon, it is most likely that the mutant
mRNA transcribed from the genomic DNA of these
patients is degraded by nonsense-mediated decay (NMD)
(Maquat 2004), a surveillance mechanism that elimi-
nates mRNAs with premature termination codons in all
but the last exon of a gene. If NMD effectively elimi-
nates the BHD mutant mRNAs, then phenotypic varia-
tion among BHD-mutation carriers may reflect the ef-
ficiency of inactivation of the BHD wild-type allele by
LOH or somatic mutation in tissues involved in the
BHD phenotype. Additionally, genetic or environmental
factors may contribute to the variability of BHD phe-
notypic expression. In support of this idea, the BHD
phenotype in patients varies within and between fami-
lies who harbor the same BHD germline mutation but
who most likely have different genetic backgrounds and/
or environmental exposures.
In an effort to identify genotype-phenotype correla-
tions, we took advantage of the large number of indi-
viduals with the c.1733ins/delC mutation in BHD and
compared the phenotype of patients who harbored the
C insertion with patients who inherited the C deletion.
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Interestingly, the frequency of renal tumors in C-inser-
tion carriers was significantly greater than the frequency
of renal tumors in C-deletion carriers. If mutant BHD
mRNA were not completely degraded by NMD but were
at least partially translated to mutant folliculin, the C-
insertion and C-deletion mutations would produce very
different aberrant BHD proteins. One could speculate
that the residual mutant protein produced in patients
with the C-insertion mutation might have a dominant-
negative effect and interfere with the wild-type BHD
protein function, leading to the development of renal
tumors. Alternatively, the residual mutant protein en-
coded by the C-insertion mutation might predispose kid-
ney cells to form a renal tumor by some as-yet-unknown
mechanism.
Among the BHD-affected family members with pu-
tative splice-site mutations in intron 9 predicted to cause
exon skipping, 7 (40%) of 17 developed renal tumors,
a significantly higher frequency than the overall fre-
quency of renal tumors seen in all mutation carriers. It
is possible that the aberrant BHD protein produced by
exon skipping might predispose to the development of
renal tumors by interacting with the wild-type BHD
protein and compromising its function. The identifica-
tion of the incorrectly spliced mutant BHD gene prod-
uct and the study of its functional properties will con-
tribute to our understanding of how mutations in BHD
lead to renal-tumor development.
Analysis of the BHD gene identified mutations in 51
of 53 NCI-study families with BHD who inherited the
BHD-affected haplotype; however, we were unable to
identify mutations in two of those families by direct se-
quencing. The BHD-affected haplotypes, which cosegre-
gated with disease in families 172 and 240, were tightly
linked to the BHD locus on chromosome 17p11.2, and
the full BHD phenotype was seen in affected individuals
from these two families. Although the entire coding se-
quence for BHD was screened, the 5′ and 3′ regulatory
regions and intronic sequences of the gene were not
examined for sequence variation that might affect BHD
expression, and the possibility of a small intragenic de-
letion cannot be ruled out. Careful evaluation of BHD
for deletions or sequence variants in regulatory regions
of the gene in families 172 and 240 is in progress.
In conclusion, we have completed mutation analysis
of the largest cohort of families with BHD reported to
date and have identified 22 different germline BHD mu-
tations in 84% (51/61) of families recruited to our study.
The majority of mutations were predicted to truncate
folliculin and most likely lead to a reduction in folliculin
expression. Renal tumors, lung cysts, spontaneous pneu-
mothorax, and FFs develop as part of the complex BHD
phenotype, with no particular correlation with muta-
tion type or location within the gene.
A mutational hotspot, a C insertion/deletion in exon
11, is frequently mutated in BHD-affected families. Re-
nal tumors developed with a higher frequency in C-
insertion carriers than in C-deletion carriers and also
more frequently in individuals who inherited a putative
splice-site mutation in intron 9. The mechanism by
which BHD acts as a tumor suppressor and its role in
the development of renal tumors, benign skin hamar-
tomas, and lung-wall defects remains to be elucidated,
which may not be possible until the BHD protein is
characterized. BHD should be considered in the differ-
ential diagnosis for patients with renal tumors with or
without skin papules and for patients with a family his-
tory of spontaneous pneumothorax.
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